This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At the initiative of Prime Minister Narendra Modi, March 7 is celebrated every year as Jan Aushadhi Diwas to enhance awareness about the scheme and promote genericmedicines. As in earlier years, week-long events have been planned at various locations across the country from March 1 to 7, 2025.
IPA leadership is committed to strengthening operational capabilities and ensuring that patients worldwide have access to affordable and quality-assured medicines.” It’s not just a goal; it is the foundation of our global leadership, and the trust placed in us.
The Indian Pharmaceutical Alliance (IPA) questions the reliance on the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) in the Ohio State University report titled, Are All Generic Drugs Created Equal? An Empirical Analysis of Generic Drug Manufacturing Location and Serious Drug Adverse Events.
Additionally, approval was recommended two genericmedicines: Enzalutamide Viatris (enzalutamide) to treat prostate cancer, and Nilotinib Accord (nilotinib) was also recommended to treat Philadelphia chromosome positive chronic myelogenous leukaemia.
To register or view the event programme click here. DIA is celebrating 60 years of bringing together leading minds to foster collaboration and advancement in global healthcare. Early-bird registration for the India Annual Meeting is available through August 10, 2024.
Significance of the Indian Pharmaceutical Market: Discussing the Indian pharmaceutical market, Mr. Kapadia noted India’s status as the world’s largest exporter of genericmedicines and third in terms of pharmaceutical production.
A spokesperson for the agency stated, “Shortages can have multiple causes, including manufacturing problems causing delays or interruption in the production, shortages of raw materials, increased demand of medicines, distribution problems, labour disruptions, and natural disasters.”
The committee adopted positive opinions for three genericmedicines: Dabigatran Etexilate Accord (dabigatran etexilate) for the prevention of venous thromboembolic events Lacosamide Adroiq (lacosamide) for epilepsy Sugammadex Adroiq (sugammadex) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.
India Pharma Inc, hailed for its prowess in the production of high-quality genericmedicines, now needs to shift from a conventional, volume-based business strategy to a value-based approach to keep it up its growth momentum. In this context, finding the right opportunities and understanding the challenges has become crucial.
The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast. Indeed, of the 281 WHO-listed essential medicines, 100% of respiratory treatments are Teva’s. The patient, he said, is the most important part of that.
Taking part in a fireside chat at the recent virtual Reuters Events: Pharma 2021 meeting, he explained how the COVID-19 pandemic had been a “wakeup call” for the industry, and spoke about the strategies that could help build the European healthcare systems of the future.
The event engaged various experts representing Duke-Margolis, FDA, the American Society of Clinical Oncology, and many others who discussed data behind cancer drug shortages and needed next steps. DM: What are some of USP’s recent efforts to strengthen drug supply chains and address shortages?
This reliance on sourcing API from other nations puts Europe’s entire manufacturing cycle at risk, especially in the event of global crises and geopolitical tensions. Alarmingly, there are now 93 active ingredients for which no European company holds a certificate.
The Committee for Medicinal Products for Human Use (CHMP) has recommended against a marketing authorisation for Leqembi (lecanemab), as a treatment for Alzheimer’s disease, during its July meeting last week. Tuznue (trastuzumab) for breast and gastric cancer.
Leveraging insights from data on USP standards distribution and usage at more than 22,000 locations worldwide and 40+ external data sets, USP launched the Medicine Supply Map in 2021 to provide an early-warning capability for supply chain vulnerabilities.
Geographic concentration and drug shortages Drugs with greater geographic concentration in manufacturing of their active pharmaceutical ingredient (API) and/or finished dose form are known to be more susceptible to possible shortages due in part to the potential concentrated impact of external events like natural disasters (e.g.,
This briefing, widely attended with bipartisan representation, included panel discussions with key thought leaders and experts on the pharmaceutical supply chain to share insights that can help to prevent future shortages and improve access to critical medicines for all patients.
FDA are co-hosting the APEC Medical Product Supply Chain Dialogue as a signature event of the U.S. In my keynote remarks, I highlighted the following elements of a strong medicines supply chain. in a platform that assesses the vulnerability of specific medicines to supply chain disruptions. To advance this goal, USP and the U.S.
Factors such as ethnicity, gender, sexual orientation and age can contribute to interindividual differences in treatment responses and risks of adverse events. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and genericmedicines.
Speaking as a fellow panelist at the event, I agreed standardization can have a significant role to play in helping with the regulatory aspects of AMT, particularly when the goal is to advance adoption of such technologies globally. The non-profit maker of essential genericmedicines was established by a group of U.S.
While the ripple effect of such an event is expected across sectors, in the pharmaceutical arena, small and mid-sized enterprises (SMEs) are predicted to be heavily impacted as the economic downturn affects plans to raise capital, amongst other things. million as part of the Build Back Better Regional Challenge.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content